|
QLT, Inc. first decision in 2008 was to enhance shareholder value by selling primary assets, including Eligard(R) - product line for prostate cancer -, Aczone(TM) - product for the treatment of acne - and Atrigel(R) drug delivery system.
As part of its strategic restructuring plan, the company planned to focus its business on its Visudyne(R) line - verteporfin for the treatment of wet age-related macular degeneration -, its Photodynamic therapy dermatology technology and its punctal plug delivery technology.
According to a spoken person, the company is "excited to embark on a new chapter as an ophthalmology-focused" one. |
